IRIS
PERSONENI, Nicola
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 1.443
NA - Nord America 746
EU - Europa 315
SA - Sud America 31
AF - Africa 14
OC - Oceania 1
Totale 2.550
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 699
SG - Singapore 628
VN - Vietnam 280
CN - Cina 261
BD - Bangladesh 167
FR - Francia 147
IT - Italia 122
HK - Hong Kong 24
CA - Canada 22
BR - Brasile 16
DE - Germania 14
IN - India 13
MX - Messico 12
JP - Giappone 11
PH - Filippine 7
TH - Thailandia 7
IQ - Iraq 6
TR - Turchia 6
UZ - Uzbekistan 6
GB - Regno Unito 5
PK - Pakistan 5
PL - Polonia 5
SE - Svezia 5
AR - Argentina 4
ID - Indonesia 4
TW - Taiwan 4
ZA - Sudafrica 4
DK - Danimarca 3
ES - Italia 3
JM - Giamaica 3
KR - Corea 3
MA - Marocco 3
AZ - Azerbaigian 2
BE - Belgio 2
BO - Bolivia 2
CO - Colombia 2
CR - Costa Rica 2
DO - Repubblica Dominicana 2
EC - Ecuador 2
EG - Egitto 2
HN - Honduras 2
LB - Libano 2
MY - Malesia 2
PY - Paraguay 2
TT - Trinidad e Tobago 2
VE - Venezuela 2
AE - Emirati Arabi Uniti 1
AU - Australia 1
BG - Bulgaria 1
BJ - Benin 1
CH - Svizzera 1
CI - Costa d'Avorio 1
CL - Cile 1
ET - Etiopia 1
FI - Finlandia 1
HU - Ungheria 1
IE - Irlanda 1
JO - Giordania 1
KE - Kenya 1
KZ - Kazakistan 1
LT - Lituania 1
MR - Mauritania 1
NI - Nicaragua 1
PA - Panama 1
PS - Palestinian Territory 1
RO - Romania 1
RS - Serbia 1
RU - Federazione Russa 1
SY - Repubblica araba siriana 1
Totale 2.550
Salva come PNG Salva come JPEG
Città #
San Jose 295
Singapore 268
Lauterbourg 142
Ho Chi Minh City 92
Ashburn 79
Boardman 78
Hanoi 59
Los Angeles 29
New York 28
Rome 25
Buffalo 18
Council Bluffs 17
Milan 17
Da Nang 16
Hong Kong 15
Santa Clara 11
Dallas 8
Haiphong 8
Beijing 6
Frankfurt am Main 6
Montreal 6
Tokyo 6
Hải Dương 5
Mexico City 5
Naples 5
Orem 5
Toronto 5
Bologna 4
Can Tho 4
Catania 4
Denver 4
Johannesburg 4
Philadelphia 4
Querétaro 4
Shanghai 4
Tashkent 4
Bangkok 3
Bari 3
Chennai 3
Dhaka 3
Jakarta 3
London 3
Nuremberg 3
Reggio Calabria 3
Thanh Mỹ Tây 3
Tân Tiến 3
Atlanta 2
Baku 2
Boston 2
Bình Phước 2
Bến Tre 2
Casablanca 2
Chicago 2
Copenhagen 2
Elk Grove Village 2
Faisalabad 2
Genoa 2
Huế 2
Istanbul 2
Kingston 2
Mumbai 2
Munich 2
Newark 2
Ottawa 2
Palermo 2
Pasadena 2
Perugia 2
Samarkand 2
Shenzhen 2
São Paulo 2
Thanh Hóa 2
Thái Bình 2
Thái Nguyên 2
Upper Marlboro 2
Verona 2
Vicenza 2
Vinh 2
Vĩnh Long 2
Warsaw 2
Ân Thi 2
Abbeville 1
Abidjan 1
Adana 1
Addis Ababa 1
Agra 1
Akron 1
Amman 1
Ancona 1
Araguaína 1
Arlington Heights 1
Astana 1
Asunción 1
Baghdad 1
Barakaldo 1
Barinas 1
Basra 1
Beauchamps 1
Beirut 1
Bekasi 1
Belgrade 1
Totale 1.408
Salva come PNG Salva come JPEG
Nome #
FOLFIRI and Cetuximab Every Second Week for First-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer According to Phosphatase and Tensin Homolog Expression : a Phase II Study 77
HER-2/neu amplification by fluorescence in situ hybridization in cytologic samples from distant metastatic sites of breast carcinoma 62
Association of candidate surrogate endpoints with overall survival in advanced biliary tract cancer 55
Factors associated with reaching maintenance therapy in patients with advanced biliary tract cancer treated with durvalumab: Real‐world results from a multicenter and multinational study 52
A Comparative Study of Methyl-BEAMing and Droplet Digital PCR for MGMT Gene Promoter Hypermethylation Detection 36
Assessment of HER2 status in patients with gastroesophageal adenocarcinoma treated with epirubicin-based chemotherapy: heterogeneity-related issues and prognostic implications 33
Negative impact of corticosteroid use on outcome in patients with advanced BTCs treated with cisplatin, gemcitabine, and durvalumab: A large real‐life worldwide population 33
Assessment of HER2 status in patients with gastroesophageal adenocarcinoma treated with epirubicin-based chemotherapy: heterogeneity-related issues and prognostic implications 33
Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Biomarkers in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab 32
Emergence of KRAS-mutation in liver metastases after an anti-EGFR treatment in patient with colorectal cancer: are we aware of the therapeutic impact of intratumor heterogeneity? 30
Clinical Usefulness of EGFR Gene Copy Number as a Predictive Marker in Colorectal Cancer Patients Treated with Cetuximab : A Fluorescent In situ Hybridization Study 29
Impact of Antibiotic Therapy in Patients with Cholangiocarcinoma Treated with Chemoimmunotherapy 29
Patterns and outcomes of subsequent therapy after immune checkpoint inhibitor discontinuation in HCC 29
Clinical Usefulness of EGFR Gene Copy Number as a Predictive Marker in Colorectal Cancer Patients Treated with Cetuximab : A Fluorescent In situ Hybridization Study 29
A Prognostic Index for Advanced Biliary Tract Cancer Treated With Cisplatin, Gemcitabine and Durvalumab: The MAGIC‐D Index 29
Correlation between the response to cetuximab alone or in combination with irinotecan and the activated/phosphorylated epidermal growth factor receptor in metastatic colorectal cancer 28
Assessment and Monitoring of Response to Systemic Treatment in Advanced Hepatocellular Carcinoma: Current Insights 27
Multidisciplinary Tumor Board in the Management of Patients with Colorectal Liver Metastases: A Single-Center Review of 847 Patients 27
ARQ 087, an oral pan- fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with advanced and/or metastatic intrahepatic cholangiocarcinoma (iCCA) 26
Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma 25
Aggressive and Multidisciplinary Local Approach to Iterative Recurrences of Colorectal Liver Metastases 25
A phase II randomized dose escalation trial of sorafenib in patients with advanced hepatocellular carcinoma 25
A Comparative Study of Methyl-BEAMing and Droplet Digital PCR for MGMT Gene Promoter Hypermethylation Detection 25
A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer : the VanGogh study 24
Are we ready for patient-reported outcomes in hepatocellular carcinoma? 24
Advanced colorectal liver metastases and surgery after preoperative chemotherapy : is response-based selection enough? 24
Phase I, pharmacokinetics, pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors 24
Antacid exposure and immunotherapy outcomes among patients with advanced hepatocellular carcinoma 24
Tivantinib: a new promising mesenchymal-epithelial transition factor inhibitor in the treatment of hepatocellular carcinoma 24
Can stereotactic body radiation therapy be a viable and efficient therapeutic option for unresectable locally advanced pancreatic adenocarcinoma? Results of a phase 2 study 23
Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma 23
ARQ 087, an oral pan- fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with advanced and/or metastatic intrahepatic cholangiocarcinoma (iCCA) 22
Tivantinib for Second-line Treatment of Advanced MET-High Hepatocellular Carcinoma: A Phase 3, Randomized, Placebo-Controlled Study (METIV-HCC) 22
Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma 22
Cabozantinib plus atezolizumab for the treatment of advanced hepatocellular carcinoma: shedding light on the preclinical rationale and clinical trials 21
Achievements in systhemic therapies in the pre-genomic era in metastatic breast cancer 21
Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma 21
Impact of corticosteroid therapy on the outcomes of hepatocellular carcinoma treated with immune checkpoint inhibitor therapy 21
Hepatocellular carcinoma: a global disease in need of individualized treatment strategies 21
NASH limits anti-tumour surveillance in immunotherapy-treated HCC 21
A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study 21
Progression patterns and therapeutic sequencing following immune checkpoint inhibition for hepatocellular carcinoma: An international observational study 20
Hepatic intra-arterial injection of Yttrium-loaded microspheres for liver metastasis secondary to colorectal cancer: best soups are sometimes made from old recipes 20
Clinical results of stereotactic body radiotherapy (SBRT) in the treatment of isolated local recurrence of pancreatic cancer after R0 surgery: A retrospective study 20
Progression of Colorectal Liver Metastases from the End of Chemotherapy to Resection: A New Contraindication to Surgery? 20
Baseline neutrophil-lymphocyte ratio and platelet-lymphocyte ratio appear predictive of immune treatment related toxicity in hepatocellular carcinoma 20
Hepatotoxicity in Patients with Hepatocellular Carcinoma on Treatment with Immune Checkpoint Inhibitors 20
Regorafenib in hepatocellular carcinoma: latest evidence and clinical implications 19
Early Antibiotic Exposure Is Not Detrimental to Therapeutic Effect from Immunotherapy in Hepatocellular Carcinoma 19
Aggressive and Multidisciplinary Local Approach to Iterative Recurrences of Colorectal Liver Metastases 19
Pembrolizumab in MMR-proficient metastatic colorectal cancer pharmacologically primed to trigger dynamic hypermutation status: The ARETHUSA trial 19
Role of stereotactic body radiation therapy in the management of oligometastatic pancreatic cancer single institution experience 18
FOLFIRI and Cetuximab Every Second Week for First-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer According to Phosphatase and Tensin Homolog Expression: A Phase II Study 18
Advanced colorectal liver metastases and surgery after preoperative chemotherapy : is response-based selection enough? 18
Angiogenesis inhibitors for advanced hepatocellular carcinoma: in search for the right partner 18
Determinants of Treatment Benefit and Post-Treatment Survival for Patients with Hepatocellular Carcinoma Enrolled in Second-Line Trials after the Failure of Sorafenib Treatment 18
Efficacy of cisplatin-gemcitabine-durvalumab in patients with advanced biliary tract cancer experiencing early vs late disease relapse after surgery: a large real-life worldwide population 18
A Phase II Randomized Dose Escalation Trial of Sorafenib in Patients with Advanced Hepatocellular Carcinoma 18
Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: a real-world study 18
Cabozantinib for the treatment of hepatocellular carcinoma 18
Tackling Refractory Metastatic Colorectal Cancer: Future Perspectives 17
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide population 17
Shaping the landscape of immune oncology in hepatocellular carcinoma 17
KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab 17
Budget impact of bimonthly use of cetuximab in patients diagnosed with metastatic colorectal cancer 17
Reply to Y. Pointreau et al 16
Can stereotactic body radiation therapy be a viable and efficient therapeutic option for unresectable locally advanced pancreatic adenocarcinoma? Results of a phase 2 study 16
Implementing Pre-Therapeutic UGT1A1 Genotyping in Clinical Practice: A Real-Life Study 16
COVID-19 and liver cancer clinical trials: not everything is lost 15
Diagnostic accuracy of 11C-choline PET/CT in comparison with CT and/or MRI in patients with hepatocellular carcinoma 15
Prognostic value of the neutrophil-to-lymphocyte ratio in hepatocellular carcinoma: an exploratory analysis from the second-line ARQ 197-215 study 15
The Systemic Inflammatory Response Identifies Patients with Adverse Clinical Outcome from Immunotherapy in Hepatocellular Carcinoma 15
Fatal Infusion Reaction to Cetuximab: The Need for Predictive Risk Factors and Safer Patient Selection 14
Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib 14
SYSTEMIC TREATMENT OF HCC IN SPECIAL POPULATIONS 14
Pharmacological inactivation of DNA repair to improve response to immunotherapy: The Arethusa trial in metastatic colorectal cancer 14
Sarcopenia is common in patients with cirrhosis and unresectable HCC treated by transarterial embolization but is not associated with increased rates of complications 14
The impact of mass spectrometry multigenic platform on the management of metastatic colorectal patients 14
Sorafenib in Hepatitis C Virus-Negative Patients With Hepatocellular Carcinoma: Don't Throw the Baby Out With the Bathwater! 14
Biliary Tract Cancers: Molecular Heterogeneity and New Treatment Options 14
Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY score 14
Biomarkers in Hepatocellular Carcinoma-Letter 14
Which choice of therapy when many are available? - Current systemic therapies for advanced hepatocellular carcinoma 14
Effect of Comorbidities in Stage II/III Colorectal Cancer Patients Treated With Surgery and Neoadjuvant/Adjuvant Chemotherapy: A Single-Center, Observational Study 14
Regorafenib in patients with refractory metastatic pancreatic cancer: a Phase II study (RESOUND) 14
Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study 13
Cabozantinib in patients with hepatocellular carcinoma failing previous treatment with sorafenib 13
The impact of molecular alterations in patients with advanced biliary tract cancer receiving cisplatin, gemcitabine and durvalumab: a large real-life worldwide population 13
Effect of Comorbidities in Stage II/III Colorectal Cancer Patients Treated With Surgery and Neoadjuvant/Adjuvant Chemotherapy: A Single-Center, Observational Study 13
Cabozantinib for the treatment of hepatocellular carcinoma 13
The Role of Cabozantinib as a Therapeutic Option for Hepatocellular Carcinoma: Current Landscape and Future Challenges 13
Budget impact of bimonthly use of cetuximab in patients diagnosed with metastatic colorectal cancer 12
Regorafenib in hepatocellular carcinoma: latest evidence and clinical implications 12
Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy 12
Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study 12
Metabolic switch in hepatocellular carcinoma patients treated with sorafenib: a proof-of-concept trial 12
Stereotactic Ablative Radiotherapy (SABR) in inoperable oligometastatic disease from colorectal cancer : a safe and effective approach 12
Atezolizumab plus bevacizumab for unresectable or metastatic hepatocellular carcinoma 12
The dual checkpoint blockade in unresectable hepatocellular carcinoma: opportunities emerging in clinical trials 12
OncoAlert round table discussions: The global COVID-19 experience 12
Totale 2.118
Salva come PNG Salva come JPEG
Categoria #
all - tutte 11.182
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 11.182
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2025/20262.713 0 0 0 0 313 363 568 275 482 240 328 144
Totale 2.713